Breakthroughs in RNA editing and radioligand therapies are poised to take biotech into a new era – driving innovation, growth and new investment opportunities Biotechnology is entering a dynamic new ...
Volatile macroeconomic events are magnified in life science and healthcare applications, which are capital intensive, long-term investments with associated regulatory, safety, and commercial risks.
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based ...
Genetic editing holds promise to treat incurable diseases, but the most popular method — CRISPR — sometimes does more harm than good. A new study from University of California San Diego and Yale ...
This study was led by Professor Kabin Xie (National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural University, Wuhan, China). The authors found that overexpression of ADARdd in rice ...
ProQR Therapeutics advances RNA editing pipeline with upcoming CTA filing for AX-0810, while enhancing leadership and maintaining strong finances. ProQR Therapeutics N.V. announced significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results